Masimo : A global medical technology company Also Know for Masimo Rad-G®

New Delhi, Indien Business Wire (02-12-2021): Masimo (Nasdaq: MASI) is a global medical technology company that develops and manufactures a wide range of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitoring devices, and automation and connectivity solutions.

Our mission is to improve patient outcomes and reduce care costs. Masimo’s pulse oximetry SET® Measure-through Motion and Low Perfusion ™ was first introduced in 1995 and has been shown to outperform other pulse oximetry technologies in over 100 independent, objective studies.

3 Masimo SET ® has also been shown to help clinicians reduce severe premature retinopathy in newborns,4 in improving examinations for CCHD in newborns 5 and when used for continuous monitoring with Masimo Patient SafetyNet ™ in post-operative wards, reducing emergency team activation, ICU transfers and costs.

6–9 Masimo SET ® is estimated to be used by more than 200 million patients in leading hospitals and other care settings worldwide 10 and is the primary pulse oximetry in nine of the top ten hospitals included in the Best Hospitals Honor Roll 2021–2022 of the6–9 Masimo SET ® is estimated to be used by more than 200 million patients in leading hospitals and other care settings worldwide 10 and is the primary pulse oximetry in nine of the top ten hospitals included in the Best Hospitals Honor Roll 2021–2022 of the6–9 Masimo SET ® is estimated to be used by more than 200 million patients in leading hospitals and other care settings worldwide 10 and is the primary pulse oximetry in nine of the top ten hospitals included in the Best Hospitals Honor Roll 2021–2022 of theUS News and World Reportare listed. 11 Masimo continues to refine SET ® and announced in 2018 that the SpO 2 accuracy of RD-SET ® sensors during movement has improved significantly. Clinicians can be even more confident that the SpO 2 levels they are relying on accurately reflect a patient’s physiological condition.

In 2005 Masimo introduced the rainbow ® pulse CO-oximetry technology. This enabled non-invasive, continuous monitoring of the blood components, for which previously invasive interventions were necessary: ​​Hemoglobin content (SpHb ®), oxygen content (SpOC ™), carboxy hemoglobin (SpCO ®), methemoglobin (SpMet ®), plethysmography variability index (Pleth Variability Index, PVi ®), RPVi ™ (rainbow ® PVi) and Oxygen Reserve Index (ORi ™).In 2013 Masimo introduced the Root ® platform for patient monitoring and connectivity.

It was designed from the start to be as flexible and expandable as possible so that additional monitoring technologies from Masimo and other providers can be added. The important additions made by Masimo include Next Generation SedLine ® brain function monitoring, O3 ® regional oximetry and ISA ™ capnography with NomoLine ® sampling lines. The Masimo family of Pulse CO-Oximeters ® for continuous or random monitoring includes devices that have been developed for use in a wide variety of clinical and non-clinical scenarios, such as: B.

wireless, portable technologies such as Radius-7 ® and Radius PPG ™, portable devices such as the Rad-67 ®,Fingertip pulse oximeters such as the MightySat ® Rx and devices such as the Rad-97 ® that are available for use in the hospital or at home. Masimo’s automation and connectivity solutions for hospitals focus on Masimo’s “Hospital Automation ™” platform and include Iris ® Gateway, iSirona ™, Patient SafetyNet, Replica ™, Halo ION ™, UniView ®, UniView: 60 ™ and Masimo SafetyNet ™. For more information about Masimo and the company’s products, visit60 ™ and Masimo SafetyNet ™. For more information about Masimo and the company’s products, visit60 ™ and Masimo SafetyNet ™.

For more information about Masimo and the company’s products, visit www.masimo.com . The published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature/ .

ORi and RPVi are not FDA-510 (k) clear and are not commercially available in the United States. Use of the Patient SafetyNet trademark is licensed from the University HealthSystem Consortium.

References

  1. Kumar H, Sarin E, Saboth P, Jaiswal A, Chaudhary N, Mohanty J, Bisht N, Tomar S, Gupta A, Panda R, Patel R, Kumar A, Gupta S, Alwadhi V. Experiences from an implementation model of an ARI diagnostic device in case management of pneumonia in children under 5 years old in peripheral health centers in India. Clin Med Insights: Pediatrics. 2021; (15) 1-10. DOI: 10.1177 / 11795565211056649.
  2. Alwadhi V, Sarin E, Kumar P, Saboth P, Khera A, Gupta S, Kumar H. Measurement accuracy of the respiratory rate measured plethysmographically with the help of a pulse oximeter in a specialized hospital in India. Pneumonia . 2020. 12: 4. https://doi.org/10.1186/s41479-020-00067-2 .
  3. For published clinical studies on pulse oximetry and the benefits of Masimo SET ®, visit our website at http://www.masimo.com . Comparative studies include independent and objective studies composed of abstracts presented at scientific meetings and articles in professional journals.
  4. Castillo, A., et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO 2 Technology. Acta Pediatr. Feb 2011; 100 (2): 188-192.
  5. de-Wahl Granelli, A., et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. Jan. 8, 2009; 338.
  6. Taenzer, A., et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology . 2010; 112 (2): 282-287.
  7. Taenzer, A., et al. Postoperative Monitoring – The Dartmouth Experience. Newsletter from the Anesthesia Patient Safety Foundation . Spring / Summer 2012.
  8. McGrath, S., et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety . July 2016; 42 (7): 293-302.
  9. McGrath, S., et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. March 14, 2020. DOI: 10.1097 / PTS.0000000000000696.
  10. Estimate: Masimo data in the archive.
  11. http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview .
  12. Masimo Rad-G ® Pulse Oximeter large trial in India

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among other things, statements regarding the potential effectiveness of the Masimo Rad-G ®. These forward-looking statements are based on current expectations of future events that are relevant to us and are subject to risks and uncertainties that are difficult to forecast and many of which are beyond our control. As a result, our actual results could differ materially and adversely from those in our forward-looking statements as a result of various risk factors.

These include risks related to our assumptions about the repeatability of clinical trial results, risks related to our belief that Masimo’s breakthrough non-invasive technologies such as Rad-G will contribute to positive clinical outcomes and patient safety, Risks that the researchers’ conclusions and findings may be inaccurate, risks related to our belief that Masimo’s non-invasive medical breakthroughs are cost-effective solutions and offer unique benefits, risks related to COVID-19, and other factors that may be relevant to the “Risk Factors” section of the current reports, which we have filed with the US Securities and Exchange Commission.

This is available free of charge from the SEC’s website at www.sec.gov. While we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove to be correct. All forward-looking statements contained in this press release are expressly restricted in their entirety by the preceding cautionary statements. You are requested not to place undue reliance on these forward-looking statements, which speak only as of today. We undertake no obligation to update, revise or clarify these statements or the “Risk Factors” contained in our most recent reports to the SEC, whether as a result of new information, future events or for any other reason, unless required by applicable securities laws .

View original version on businesswire.com

CONTACT: Masimo
Evan Lamb
+1 949 396 3376
[email protected]
KEYWORD: EUROPE SWITZERLAND INDIA ASIA PACIFIC
INDUSTRY KEYWORD: HOSPITALS HEALTH CLINICAL TRIALS MEDICAL DEVICES
SOURCE: Masimo
Copyright Business Wire 2021.
PUB: 11/30/2021 02:29 AM / DISC: 11/30/2021 02:29 AM